Sexually Transmitted Infection Prevalence Among Women at Risk for HIV Exposure Initiating Safer Conception Care in Rural, Southwestern Uganda.


Journal

Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 15 5 2020
medline: 20 4 2021
entrez: 15 5 2020
Statut: ppublish

Résumé

Knowledge of sexually transmitted infection (STI) prevalence and risk factors is important to the development of tenofovir-based preexposure prophylaxis (PrEP) and safer conception programming. We introduced STI screening among women at risk for HIV exposure who were participating in a safer conception study in southwestern Uganda. We enrolled 131 HIV-uninfected women, planning for pregnancy with a partner living with HIV or of unknown HIV serostatus (2018-2019). Women were offered comprehensive safer conception counseling, including PrEP. Participants completed interviewer-administered questionnaires detailing sociodemographics and sexual history. We integrated laboratory screening for chlamydia, gonorrhea, trichomoniasis, and syphilis as a substudy to assess STI prevalence. Multivariable logistic regression was used to determine correlates. Ninety-four women completed STI screening (72% of enrolled). Median age was 30 (interquartile range, 26-34) years, and 94% chose PrEP as part of safer conception care. Overall, 24% had STIs: 13% chlamydia, 2% gonorrhea, 6% trichomoniasis, 6% syphilis, and 3% ≥2 STI. Sexually transmitted infection prevalence was associated with younger age (adjusted odds ratio [AOR], 0.87; 95% confidence interval [CI], 0.77-0.99), prior stillbirth (AOR, 5.04; 95% CI, 1.12-22.54), and not feeling vulnerable to HIV (AOR, 16.33; 95% CI, 1.12-237.94). We describe a 24% curable STI prevalence among women at risk for HIV exposure who were planning for pregnancy. These data highlight the importance of integrating laboratory-based STI screening into safer conception programs to maximize the health of HIV-affected women, children, and families.

Sections du résumé

BACKGROUND
Knowledge of sexually transmitted infection (STI) prevalence and risk factors is important to the development of tenofovir-based preexposure prophylaxis (PrEP) and safer conception programming. We introduced STI screening among women at risk for HIV exposure who were participating in a safer conception study in southwestern Uganda.
METHODS
We enrolled 131 HIV-uninfected women, planning for pregnancy with a partner living with HIV or of unknown HIV serostatus (2018-2019). Women were offered comprehensive safer conception counseling, including PrEP. Participants completed interviewer-administered questionnaires detailing sociodemographics and sexual history. We integrated laboratory screening for chlamydia, gonorrhea, trichomoniasis, and syphilis as a substudy to assess STI prevalence. Multivariable logistic regression was used to determine correlates.
RESULTS
Ninety-four women completed STI screening (72% of enrolled). Median age was 30 (interquartile range, 26-34) years, and 94% chose PrEP as part of safer conception care. Overall, 24% had STIs: 13% chlamydia, 2% gonorrhea, 6% trichomoniasis, 6% syphilis, and 3% ≥2 STI. Sexually transmitted infection prevalence was associated with younger age (adjusted odds ratio [AOR], 0.87; 95% confidence interval [CI], 0.77-0.99), prior stillbirth (AOR, 5.04; 95% CI, 1.12-22.54), and not feeling vulnerable to HIV (AOR, 16.33; 95% CI, 1.12-237.94).
CONCLUSIONS
We describe a 24% curable STI prevalence among women at risk for HIV exposure who were planning for pregnancy. These data highlight the importance of integrating laboratory-based STI screening into safer conception programs to maximize the health of HIV-affected women, children, and families.

Identifiants

pubmed: 32404858
doi: 10.1097/OLQ.0000000000001197
pmc: PMC7363531
mid: NIHMS1590925
pii: 00007435-202008000-00014
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e24-e28

Subventions

Organisme : Doris Duke Charitable Foundation
ID : 2016094
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010543
Pays : United States
Organisme : NIMH NIH HHS
ID : K24 MH114732
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007433
Pays : United States

Références

Hum Reprod. 2010 Jul;25(7):1722-33
pubmed: 20410218
Bull World Health Organ. 2013 Mar 1;91(3):217-26
pubmed: 23476094
Sex Transm Dis. 2017 Mar;44(3):135-140
pubmed: 28178109
Lancet. 2016 Feb 6;387(10018):587-603
pubmed: 26794078
J Int AIDS Soc. 2015 Apr 24;18:19866
pubmed: 25912181
BMC Infect Dis. 2018 Oct 3;18(1):499
pubmed: 30285705
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
Biom J. 2018 May;60(3):431-449
pubmed: 29292533
Sex Transm Dis. 2005 Jun;32(6):351-7
pubmed: 15912081
Bull World Health Organ. 2019 Aug 01;97(8):548-562P
pubmed: 31384073
AIDS Behav. 2018 Jun;22(6):1713-1724
pubmed: 28501964
Lancet. 2010 Apr 24;375(9724):1482-90
pubmed: 20223514
J Infect Dis. 2010 Jun 15;201 Suppl 2:S178-89
pubmed: 20524235
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Sex Transm Dis. 2013;2013:358402
pubmed: 26316957
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
Sex Transm Dis. 2018 Dec;45(12):829-833
pubmed: 29944643

Auteurs

Moran Owembabazi (M)

Massachusetts General Hospital, Mbarara University of Science and Technology Global Health Collaborative, Boston, MA, and Mbarara, Uganda.

Kasey O'Neil (K)

Massachusetts General Hospital, Mbarara University of Science and Technology Global Health Collaborative, Boston, MA, and Mbarara, Uganda.

Paul Kato Kalyebara (PK)

Mbarara Regional Referral Hospital and Mbarara University of Science and Technology, Mbarara, Uganda.

Winnie Muyindike (W)

Mbarara Regional Referral Hospital and Mbarara University of Science and Technology, Mbarara, Uganda.

Nicholas Musinguzi (N)

Massachusetts General Hospital, Mbarara University of Science and Technology Global Health Collaborative, Boston, MA, and Mbarara, Uganda.

David R Bangsberg (DR)

OHSU PSU School of Public Health, Portland, OR.

Jeanne M Marrazzo (JM)

Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL.

Angela Kaida (A)

Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH